Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 143

Cited In for PubMed (Select 22488764)

1.

Liver steatosis is associated with insulin resistance in skeletal muscle rather than in the liver in Japanese patients with non-alcoholic fatty liver disease.

Kato K, Takeshita Y, Misu H, Zen Y, Kaneko S, Takamura T.

J Diabetes Investig. 2015 Mar;6(2):158-63. doi: 10.1111/jdi.12271. Epub 2014 Sep 15.

2.

Lipidomic-based investigation into the regulatory effect of Schisandrin B on palmitic acid level in non-alcoholic steatotic livers.

Kwan HY, Niu X, Dai W, Tong T, Chao X, Su T, Chan CL, Lee KC, Fu X, Yi H, Yu H, Li T, Tse AK, Fong WF, Pan SY, Lu A, Yu ZL.

Sci Rep. 2015 Mar 13;5:9114. doi: 10.1038/srep09114.

3.

Epidemiology and Natural History of Non-alcoholic Fatty Liver Disease.

Mishra A, Younossi ZM.

J Clin Exp Hepatol. 2012 Jun;2(2):135-44. doi: 10.1016/S0973-6883(12)60102-9. Epub 2012 Jul 21.

4.
5.

Micro RNAs in the development of non-alcoholic fatty liver disease.

Gerhard GS, DiStefano JK.

World J Hepatol. 2015 Feb 27;7(2):226-34. doi: 10.4254/wjh.v7.i2.226. Review.

6.

Recent advances in dietary supplementation, in treating non-alcoholic fatty liver disease.

Eslamparast T, Eghtesad S, Poustchi H, Hekmatdoost A.

World J Hepatol. 2015 Feb 27;7(2):204-12. doi: 10.4254/wjh.v7.i2.204. Review.

7.

An improved method for liver diseases detection by ultrasound image analysis.

Owjimehr M, Danyali H, Helfroush MS.

J Med Signals Sens. 2015 Jan-Mar;5(1):21-9.

8.

Trypanosoma cruzi infection is a potent risk factor for non-alcoholic steatohepatitis enhancing local and systemic inflammation associated with strong oxidative stress and metabolic disorders.

Onofrio LI, Arocena AR, Paroli AF, Cabalén ME, Andrada MC, Cano RC, Gea S.

PLoS Negl Trop Dis. 2015 Feb 10;9(2):e0003464. doi: 10.1371/journal.pntd.0003464. eCollection 2015 Feb.

9.

Sonographic assessment of fatty liver: intraobserver and interobserver variability.

Cengiz M, Sentürk S, Cetin B, Bayrak AH, Bilek SU.

Int J Clin Exp Med. 2014 Dec 15;7(12):5453-60. eCollection 2014.

10.

Characteristics of hepatocellular carcinoma in cirrhotic and non-cirrhotic non-alcoholic fatty liver disease.

Leung C, Yeoh SW, Patrick D, Ket S, Marion K, Gow P, Angus PW.

World J Gastroenterol. 2015 Jan 28;21(4):1189-96. doi: 10.3748/wjg.v21.i4.1189.

11.

Identification of novel clinical factors associated with hepatic fat accumulation in extreme obesity.

Gerhard GS, Benotti P, Wood GC, Chu X, Argyropoulos G, Petrick A, Strodel WE, Gabrielsen JD, Ibele A, Still CD, Kingsley C, DiStefano J.

J Obes. 2014;2014:368210. doi: 10.1155/2014/368210. Epub 2014 Dec 24.

12.

A 25-year-old woman with type 2 diabetes and liver disease.

Junker AE, Gluud LL, Pedersen J, Langhoff JL, Holst JJ, Knop FK, Vilsbøll T.

Case Rep Gastroenterol. 2014 Dec 12;8(3):398-403. doi: 10.1159/000369968. eCollection 2014 Sep-Dec.

13.

O-GlcNAc: A Bittersweet Switch in Liver.

Zhang K, Yin R, Yang X.

Front Endocrinol (Lausanne). 2014 Dec 17;5:221. doi: 10.3389/fendo.2014.00221. eCollection 2014. Review.

14.

Serum cytokeratin 18 fragment level as a noninvasive biomarker for non-alcoholic fatty liver disease.

Aida Y, Abe H, Tomita Y, Nagano T, Seki N, Sugita T, Itagaki M, Ishiguro H, Sutoh S, Aizawa Y.

Int J Clin Exp Med. 2014 Nov 15;7(11):4191-8. eCollection 2014.

15.

The role of dietary sugars and de novo lipogenesis in non-alcoholic fatty liver disease.

Moore JB, Gunn PJ, Fielding BA.

Nutrients. 2014 Dec 10;6(12):5679-703. doi: 10.3390/nu6125679.

16.

SteatoNet: the first integrated human metabolic model with multi-layered regulation to investigate liver-associated pathologies.

Naik A, Rozman D, Belič A.

PLoS Comput Biol. 2014 Dec 11;10(12):e1003993. doi: 10.1371/journal.pcbi.1003993. eCollection 2014 Dec.

17.

Focus on emerging drugs for the treatment of patients with non-alcoholic fatty liver disease.

Federico A, Zulli C, de Sio I, Del Prete A, Dallio M, Masarone M, Loguercio C.

World J Gastroenterol. 2014 Dec 7;20(45):16841-57. doi: 10.3748/wjg.v20.i45.16841.

18.

Serum amylase levels are decreased in Chinese non-alcoholic fatty liver disease patients.

Yao J, Zhao Y, Zhang J, Hong Y, Lu H, Wu J.

Lipids Health Dis. 2014 Dec 7;13:185. doi: 10.1186/1476-511X-13-185.

19.

The role of intestinal bacteria overgrowth in obesity-related nonalcoholic fatty liver disease.

Ferolla SM, Armiliato GN, Couto CA, Ferrari TC.

Nutrients. 2014 Dec 3;6(12):5583-99. doi: 10.3390/nu6125583.

20.

Circulating extracellular vesicles with specific proteome and liver microRNAs are potential biomarkers for liver injury in experimental fatty liver disease.

Povero D, Eguchi A, Li H, Johnson CD, Papouchado BG, Wree A, Messer K, Feldstein AE.

PLoS One. 2014 Dec 3;9(12):e113651. doi: 10.1371/journal.pone.0113651. eCollection 2014.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk